Effects of Statin Therapy on the Development and Progression of Heart Failure: Mechanisms and Clinical Trials

Shepherd, 1995, Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group, N Engl J Med, 333, 1301, 10.1056/NEJM199511163332001

Torre-Amione, 1999, The syndrome of heart failure: emerging concepts in the understanding of its pathogenesis and treatment, Curr Opin Cardiol, 14, 193, 10.1097/00001573-199905000-00001

1998, Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group, N Engl J Med, 339, 1349, 10.1056/NEJM199811053391902

Sacks, 1996, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators, N Engl J Med, 335, 1001, 10.1056/NEJM199610033351401

Lystash, 1995, Early versus late congestive heart failure after initially uncomplicated anterior wall acute myocardial infarction, Am J Cardiol, 75, 653, 10.1016/S0002-9149(99)80648-1

Uretsky, 2000, Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial, Circulation, 102, 611, 10.1161/01.CIR.102.6.611

Keidar, 1994, Pravastatin inhibits cellular cholesterol synthesis and increases low density lipoprotein receptor activity in macrophages: in vitro and in vivo studies, Br J Clin Pharmacol, 38, 513, 10.1111/j.1365-2125.1994.tb04392.x

2002, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial, Lancet, 360, 7, 10.1016/S0140-6736(02)09327-3

Remme, 2000, Overview of the relationship between ischemia and congestive heart failure, Clin Cardiol, 23, IV4, 10.1002/clc.4960230703

Vaughan, 1996, Statins do more than just lower cholesterol, Lancet, 348, 1079, 10.1016/S0140-6736(96)05190-2

Rosenson, 1998, Antiatherothrombotic properties of statins: implications for cardiovascular event reduction, JAMA, 279, 1643, 10.1001/jama.279.20.1643

Kureishi, 2000, The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals, Nat Med, 6, 1004, 10.1038/79510

Qi, 1999, Improvement of endocardial and vascular endothelial function on myocardial performance by captopril treatment in postinfarct rat hearts, Circulation, 100, 1338, 10.1161/01.CIR.100.12.1338

Kinugawa, 2000, Treatment with dimethylthiourea prevents left ventricular remodeling and failure after experimental myocardial infarction in mice: role of oxidative stress, Circ Res, 87, 392, 10.1161/01.RES.87.5.392

Laufs, 1998, Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors, Circulation, 97, 1129, 10.1161/01.CIR.97.12.1129

von Haehling, 2003, Statins and the role of nitric oxide in chronic heart failure, Heart Fail Rev, 8, 99, 10.1023/A:1022103222857

Datta, 1999, Cellular survival: a play in three Akts, Genes Dev, 13, 2905, 10.1101/gad.13.22.2905

Guo, 1998, Nitric oxide-induced downregulation of Cdk2 activity and cyclin A gene transcription in vascular smooth muscle cells, Circulation, 97, 2066, 10.1161/01.CIR.97.20.2066

Francis, 1998, Interleukin-1 in myocardium and coronary arteries of patients with dilated cardiomyopathy, J Mol Cell Cardiol, 30, 215, 10.1006/jmcc.1997.0592

Di Napoli, 2005, Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts, Cardiovasc Res, 66, 462, 10.1016/j.cardiores.2005.02.008

Nachtigal, 2005, The changes in the endothelial expression of cell adhesion molecules and iNOS in the vessel wall after the short-term administration of simvastatin in rabbit model of atherosclerosis, J Pharm Pharmacol, 57, 197, 10.1211/0022357055353

Huang, 2003, HMG-CoA reductase inhibitors inhibit inducible nitric oxide synthase gene expression in macrophages, J Biomed Sci, 10, 396, 10.1007/BF02256431

Chen, 2000, Fluvastatin upregulates inducible nitric oxide synthase expression in cytokine-stimulated vascular smooth muscle cells, Hypertension, 36, 923, 10.1161/01.HYP.36.6.923

Hattori, 2002, Statin enhances cytokine-mediated induction of nitric oxide synthesis in vascular smooth muscle cells, Cardiovasc Res, 54, 649, 10.1016/S0008-6363(02)00266-3

Yamamoto, 2003, HMG-CoA reductase inhibitor enhances inducible nitric oxide synthase expression in rat vascular smooth muscle cells; involvement of the Rho/Rho kinase pathway, Atherosclerosis, 166, 213, 10.1016/S0021-9150(02)00329-5

Katz, 1999, Decreased activity of the L-arginine-nitric oxide metabolic pathway in patients with congestive heart failure, Circulation, 99, 2113, 10.1161/01.CIR.99.16.2113

Hernandez-Perera, 1998, Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells, J Clin Invest, 101, 2711, 10.1172/JCI1500

Goldstein, 1990, Regulation of the mevalonate pathway, Nature, 343, 425, 10.1038/343425a0

Casey, 1995, Protein lipidation in cell signaling, Science, 268, 221, 10.1126/science.7716512

Jones, 2003, Endothelial nitric oxide synthase overexpression attenuates congestive heart failure in mice, Proc Natl Acad Sci U S A, 100, 4891, 10.1073/pnas.0837428100

Williams, 1998, Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys, J Am Coll Cardiol, 31, 684, 10.1016/S0735-1097(97)00537-8

Egashira, 1994, Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia, Circulation, 89, 2519, 10.1161/01.CIR.89.6.2519

Stroes, 1995, Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication, Lancet, 346, 467, 10.1016/S0140-6736(95)91322-X

Cohn, 1993, The Vasodilator-Heart Failure Trials (V-HeFT). Mechanistic data from the VA Cooperative Studies. Introduction, Circulation, 87, VI1

Strehlow, 2000, Angiotensin AT1 receptor over-expression in hypercholesterolaemia, Ann Med, 32, 386, 10.3109/07853890008995944

Cohn, 2001, A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure, N Engl J Med, 345, 1667, 10.1056/NEJMoa010713

Mitani, 1996, Inhibitory effects of fluvastatin, a new HMG-CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol-fed rabbits, Br J Pharmacol, 119, 1269, 10.1111/j.1476-5381.1996.tb16032.x

Luo, 1999, Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis, Clin Exp Pharmacol Physiol, 26, 903, 10.1046/j.1440-1681.1999.03165.x

Oi, 1999, Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells, Eur J Pharmacol, 376, 139, 10.1016/S0014-2999(99)00282-4

Takemoto, 2001, Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy, J Clin Invest, 108, 1429, 10.1172/JCI13350

Pliquett, 2003, Simvastatin normalizes autonomic neural control in experimental heart failure, Circulation, 107, 2493, 10.1161/01.CIR.0000065606.63163.B9

Packer, 1995, Is tumor necrosis factor an important neurohormonal mechanism in chronic heart failure?, Circulation, 92, 1379, 10.1161/01.CIR.92.6.1379

Levine, 1990, Elevated circulating levels of tumor necrosis factor in severe chronic heart failure, N Engl J Med, 323, 236, 10.1056/NEJM199007263230405

Pinsky, 1995, The lethal effects of cytokine-induced nitric oxide on cardiac myocytes are blocked by nitric oxide synthase antagonism or transforming growth factor beta, J Clin Invest, 95, 677, 10.1172/JCI117713

Pahan, 1997, Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages, J Clin Invest, 100, 2671, 10.1172/JCI119812

Rosenson, 1999, Inhibition of proinflammatory cytokine production by pravastatin, Lancet, 353, 983, 10.1016/S0140-6736(98)05917-0

Ridker, 1999, Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators, Circulation, 100, 230, 10.1161/01.CIR.100.3.230

Riesen, 2002, Short-term effects of atorvastatin on C-reactive protein, Eur Heart J, 23, 794, 10.1053/euhj.2001.2967

Albert, 2001, Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study, JAMA, 286, 64, 10.1001/jama.286.1.64

Plenge, 2002, Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction, Circulation, 106, 1447, 10.1161/01.CIR.0000029743.68247.31

Nissen, 2005, Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease, N Engl J Med, 352, 29, 10.1056/NEJMoa042000

Ridker, 2005, C-reactive protein levels and outcomes after statin therapy, N Engl J Med, 352, 20, 10.1056/NEJMoa042378

Cannon, 2004, Intensive versus moderate lipid lowering with statins after acute coronary syndromes, N Engl J Med, 350, 1495, 10.1056/NEJMoa040583

Thomas, 1998, Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy, Circulation, 97, 1708, 10.1161/01.CIR.97.17.1708

Ducharme, 2000, Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction, J Clin Invest, 106, 55, 10.1172/JCI8768

Aikawa, 2001, An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro, Circulation, 103, 276, 10.1161/01.CIR.103.2.276

Bellosta, 1998, HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages, Arterioscler Thromb Vasc Biol, 18, 1671, 10.1161/01.ATV.18.11.1671

Bauersachs, 2001, Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction, Circulation, 104, 982, 10.1161/hc3401.095946

Hayashidani, 2002, Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction, Circulation, 105, 868, 10.1161/hc0702.104164

Dechend, 2001, Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, Circulation, 104, 576, 10.1161/hc3001.092039

Young-Xu, 2003, Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease, Am J Cardiol, 92, 1379, 10.1016/j.amjcard.2003.08.040

Lewis, 1998, Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial, Ann Intern Med, 129, 681, 10.7326/0003-4819-129-9-199811010-00002

LaRosa, 2005, Intensive lipid lowering with atorvastatin in patients with stable coronary disease, N Engl J Med, 352, 1425, 10.1056/NEJMoa050461

Aronow, 2002, Frequency of congestive heart failure in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol > or = 125 mg/dl treated with statins versus no lipid-lowering drug, Am J Cardiol, 90, 147, 10.1016/S0002-9149(02)02438-4

Segal, 2000, Effects of HMG-CoA reductase inhibitors (statins) in patients with heart failure, Eur J Heart Failure, 2, 96, 10.1016/S1388-9842(00)80342-6

Ray, 2005, Statin use and survival outcomes in elderly patients with heart failure, Arch Intern Med, 165, 62, 10.1001/archinte.165.1.62

Node, 2003, Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy, Circulation, 108, 839, 10.1161/01.CIR.0000084539.58092.DE

Mozaffarian, 2005, The effects of atorvastatin (10 mg) on systemic inflammation in heart failure, Am J Cardiol, 96, 1699, 10.1016/j.amjcard.2005.07.092

Sola, 2006, Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure, J Am Coll Cardiol, 47, 332, 10.1016/j.jacc.2005.06.088

Bleske, 2006, Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level, J Am Coll Cardiol, 47, 338, 10.1016/j.jacc.2005.06.087

Aurigemma, 2004, Clinical practice. Diastolic heart failure, N Engl J Med, 351, 1097, 10.1056/NEJMcp022709

Redfield, 2004, Understanding “diastolic” heart failure, N Engl J Med, 350, 1930, 10.1056/NEJMp048064

Senni, 2001, Heart failure with preserved systolic function. A different natural history?, J Am Coll Cardiol, 38, 1277, 10.1016/S0735-1097(01)01567-4

Fukuta, 2005, Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report, Circulation, 112, 357, 10.1161/CIRCULATIONAHA.104.519876

Fonarow, 2003, Cholesterol and mortality in heart failure: the bad gone good?, J Am Coll Cardiol, 42, 1941, 10.1016/j.jacc.2003.09.005

Mortensen, 1997, Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors, Mol Aspects Med, 18, S137, 10.1016/S0098-2997(97)00014-9

Kjekshus, 2005, A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics, Eur J Heart Fail, 7, 1059, 10.1016/j.ejheart.2005.09.005

Tavazzi, 2004, Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure, Eur J Heart Fail, 6, 635, 10.1016/j.ejheart.2004.03.001